ZS04
    In cooperation with Shanghai Cancer Institute (SCI), Zensun used screening to identify a monoclonal antibody (mAb) that specifically recognizes human small cell lung cancer(SCLC) cells by using various strains of human small cell lung cancer cells as immunogen. This mAb specifically recognizes the small cell lung cancer cells without cross-reacting with normal tissues and other tumor tissues (Zensun patent no. ZL01126394.6). By linking this mAb to cytotoxic drugs, Zensun has developed a new drug targeted against small cell lung cancer. This conjugate enables the cytotoxic drugs to release locally in tumors, resulting in significantly improved safety, greatly reduced side effects, and enhanced drug efficacy. The results of preclinical studies show that radioisotope-mAb conjugates significantly inhibit tumor growth and prolong survival in an animal model compared with the use of radioisotopes or toxic agents alone.

About small cell lung cancer
    SCLC represents approximately 15-20% of lung cancers, and is characterized by high-grade malignancy, a short doubling time, early and extensive metastasis, a high recurrence rate, and a low long-term survival rate. For untreated SCLC patients, the median survival time is only 2-4 months and the overall 5-year survival rate is only 5-10%[1]. There is an extreme lack of therapeutic approaches for this fatal malignant tumor and no new therapies have been developed for over 30 years [2, 3].

Reference
[1]National Cancer Institute, Small Cell Lung Cancer Treatment – Health Professional Version.
[2]Joshi M, Ayoola A, Belani C P, et al. Small-cell lung cancer: an update on targeted therapies.[J]. Advances in Experimental Medicine and Biology, 2013: 385-404.
[3]William W N, Glisson B S. Novel strategies for the treatment of small-cell lung carcinoma [J]. Nature reviews Clinical oncology, 2011, 8(10): 611-619.
 
Clinical Trials Recruiting Participants